Hexedrone
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Hexedrone (2-(methylamino)-1-phenylhexan-1-one) is a synthetic stimulant of the cathinone class. It is the closest structural relative of N-ethylhexedrone, differing by a single carbon on the amine group. It blocks the brain's dopamine and norepinephrine recycling mechanisms, producing focused stimulation and euphoria.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamines, cocaine, cathinones +1 moreamphetamines, cocaine, cathinones, dopaminergic stimulants show less
Poland first reported a seized hexedrone sample to European drug monitoring authorities in July 2013,[3] and chemical identity was formally confirmed in 2017.[4] Its N-ethyl cousin N-ethylhexedrone rapidly dominated European stimulant markets,[5] leaving hexedrone a minor figure. Hexedrone itself remains a rare presence on novel psychoactive substance markets, with no medical use and no recognized street identity.
Subjective effects include euphoria, focus enhancement, thought acceleration, and a strong compulsive redosing urge.[6] The experience is narrowly stimulant — dopamine-driven, without the warmth of mixed cathinones like mephedrone. Cardiovascular strain, anxiety, and a dysphoric comedown are characteristic unwanted effects.
Dependence liability is moderate to high — potent dopamine blockade drives compulsive redosing that can escalate into binge use.[7] The safety margin is narrow: fatal and non-fatal blood concentrations in N-ethyl structural analog cases were not far apart.[5][8] No controlled study has been published for hexedrone itself — current understanding rests entirely on analog data and user reports.[6]
History[edit]
Discovery
Hexedrone attracted no serious attention until July 2013, when Poland reported a seized sample to the EMCDDA Early Warning System — the first documented appearance of hexedrone as a novel psychoactive substance.[3] Formal chemical identification came in 2017, when researchers confirmed its structure alongside three other novel cathinones from Polish drug seizures.[4]
Market trajectory
Hexedrone was quickly eclipsed by its N-ethyl relative, N-ethylhexedrone (NEH), which appeared on European markets in late 2015 and spread to five countries within three months.[3] By 2017, NEH had become the most frequently seized stimulant designer drug in Hungary.[5] This dominance explains why almost all published research concerns NEH rather than hexedrone.
Regulatory response
NEH was permanently placed in US Schedule I in June 2022[9] and added to the UN Convention on Psychotropic Substances in March 2020.[10] Hexedrone itself has not been individually scheduled at the UN or US federal level, though generic cathinone laws in several countries cover it.
The name follows standard cathinone naming: "hex-" for the six-carbon backbone, "-edrone" from cathinone. Hexedrone sits in a homologous series — buphedrone (C4), pentedrone (C5), hexedrone (C6), heptedrone (C7) — each named for its chain length. It never acquired street names or a distinct subcultural identity, remaining a catalog entry rather than a recognized substance among stimulant users.
Chemistry[edit]
Structural class
Hexedrone is a substituted cathinone — a β-keto amphetamine within the phenethylamine family. It is built on the cathinone scaffold, the natural stimulant alkaloid of the khat plant, extended with an N-methyl group and a four-carbon chain at the α-position.
It sits in a homologous N-methyl cathinone series: buphedrone (C4), pentedrone (C5), hexedrone (C6), heptedrone (C7).
Molecular properties
| Molecular formula | C₁₃H₁₉NO |
| Molecular weight | 205.30 g/mol |
Values confirmed via PubChem.[11] Replacing the N-methyl group with N-ethyl produces N-ethylhexedrone, the more widely studied structural partner.
Pharmacology[edit]
Mechanism of action
Hexedrone is a norepinephrine-dopamine reuptake inhibitor. It blocks the transporters that clear dopamine and norepinephrine from the synapse, causing both to accumulate. This classification is established for N-ethylhexedrone, which shows no monoamine release at any transporter;[1] hexedrone, differing by one carbon, is expected to share this mechanism.
Hexedrone is sometimes misclassified as a monoamine releasing agent. Published transporter data for N-ethylhexedrone show no releasing activity at any monoamine transporter.[1] The compound acts solely through reuptake inhibitor.
Its high selectivity for dopamine over serotonin transporters places it in the same pharmacological category as cocaine — predominantly stimulant and euphoric, with little of the emotional warmth seen in mixed-mechanism cathinones like mephedrone.
Pharmacokinetics
No human pharmacokinetic data exist for hexedrone. Based on N-ethylhexedrone studies, the compound has a plasma half-life of 19–28 hours[7] and is detectable in urine for up to 10 days — far longer than the 1–4 hour subjective peak. In one controlled intranasal study, NEH appeared in oral fluid within the first hour of dosing.[12]
Neuroscience[edit]
Where it acts
As a potent DAT blocker, hexedrone raises dopamine levels in the brain's reward center — the nucleus accumbens. This produces the euphoria and reinforcement drive that underlies compulsive use.[1] Norepinephrine buildup[1] sharpens focus at lower doses, but at higher doses tips into impaired judgment — decision impairment and compulsive redosing.
Why it matters
DAT-selective stimulants like hexedrone amplify the brain's wanting signal — the drive to seek the drug — more than the liking signal, the actual pleasure. This is why the redosing urge so often exceeds the high itself.
The low mood, fatigue, and emotional flatness that follow heavy use[7] reflect a temporary dopamine crash. Sustained transporter blockade depletes the brain's dopamine reserves; the rebound effect state is low until stores replenish.
No neuroimaging or electrophysiology data exist for hexedrone or N-ethylhexedrone. Whether hexedrone causes dopaminergic neurotoxicity at recreational doses is unknown — in laboratory tests, the N-ethyl cathinone series is more toxic to nerve cells than methamphetamine.[13] Dose-to-transporter occupancy and psychosis vulnerability profiles remain entirely uncharacterized.
Subjective Effects[edit]
Hexedrone produces a focused, narrowly stimulant experience. At lower doses it reads as heightened alertness and purposeful energy. As dose increases, euphoria builds — but the compulsive compulsive redosing urge consistently outpaces the pleasure itself.
The experience sits closest to pentedrone in the cathinone series and shares cocaine's mechanism — pure dopamine and norepinephrine reuptake inhibitor without broader receptor activity. Compared to mephedrone, it is narrower: more purely stimulant, less emotionally open, and with a sharper drop into dysphoria when it ends.
Effect Grid
Clear stimulant effects dominate: euphoria, enhanced focus, thought acceleration, and increased sociability form the core experience. Analysis enhancement and motivation enhancement are noticeable. Music enhancement and immersion enhancement may be present. Disinhibition and ego inflation emerge at this tier.
Physical effects become apparent — appetite suppression, vasoconstriction, and bruxism are common. Heart rate and blood pressure are elevated. Excessive sweating and dehydration sensation may occur. Spontaneous body sensations are possible.
The compulsive redosing urge becomes a defining feature at common doses. The short total duration (1–4 hours) combined with this urge creates significant binge risk. Aftereffects — including irritability, low mood, and cognitive fatigue — may persist 1–12 hours. Sleep is impossible for several hours after the last dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Tinnitus
Pupil dilation · Dry mouth · Insomnia · Physical fatigue · Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Restlessness · Dehydration sensation · Nausea · Bodily lightness · Bruxism · Headache · Nasal congestion · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Trembling · Dizziness · Tingling / electric sensations · Motor control enhancement · Involuntary body movements · Vibrations / buzzing · Tactile hallucination
Body high · Excessive sweating · Heart rate perception changes · Muscle tension · Restlessness · Dehydration sensation · Nausea · Bodily lightness · Bruxism · Headache · Nasal congestion · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tactile euphoria · Trembling · Dizziness · Tingling / electric sensations · Motor control enhancement · Involuntary body movements · Vibrations / buzzing · Tactile hallucination
Focus enhancement · Motivation enhancement · Motivation suppression · Information processing enhancement · Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive impairment · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Confusion · Thought disorganization · Thought loops
Analysis enhancement · Cognitive dysphoria · Cognitive flexibility · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive impairment · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Confusion · Thought disorganization · Thought loops
Irritability · Dysphoria · Emotional lability · Mania
Communication enhancement · Sociability enhancement · Social connection · Flow state
Timeline
Initial alertness and subtle mood shift emerge. A faint increase in heart rate may be noticed as the compound begins to take effect.
Rapidly building stimulation with euphoria emerging. Focus sharpens and sociability increases as dopaminergic effects intensify.
Full dopaminergic stimulation — euphoria, focus enhancement, thought acceleration, and appetite suppression are at maximum intensity. The compulsive redosing urge is strongest here. Cardiovascular effects (tachycardia, vasoconstriction) are most pronounced.
Effects diminish gradually. Motivation to redose persists even as euphoria fades. Irritability and restlessness may emerge as the stimulant state recedes.
Post-acute dysphoria phase — cognitive fatigue, low mood, anhedonia, and motivation suppression predominate. Appetite returns. Sleep may remain difficult for several hours.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamines · cocaine · cathinones
Toxicity
Acute toxicity
No controlled toxicity studies exist for hexedrone or N-ethylhexedrone. All acute data come from case reports.safety citation needed
Two fatal NEH intoxications have been published. A 23-year-old with pre-existing heart disease died after combining NEH with a synthetic cannabinoid; postmortem blood NEH was 285 ng/mL.[5] A 21-year-old with no known conditions developed body temperature exceeding 41 °C, heart rate above 160 bpm, and acute kidney failure, dying within hours at a postmortem concentration of 145 ng/mL.[8]
Non-fatal severe cases have required mechanical ventilation after hospitalization.[7] The gap between non-fatal blood levels (up to ~97 ng/mL) and fatal concentrations (145–285 ng/mL) indicates a limited safety margin.[5][7]
Heart and circulation
Hexedrone-class compounds push the cardiovascular system into overdrive: rapid heart rate, elevated blood pressure, vasoconstriction, and dangerous overheating.[14] Pre-existing heart conditions substantially increase the risk of fatal outcome.[5]
Cell toxicity
In laboratory tests, the N-ethyl cathinone series is more toxic to nerve-like cells than methamphetamine, with toxicity increasing as the carbon chain lengthens.[13] Whether hexedrone causes nerve damage in living organisms at recreational doses has not been studied.
Psychological risks
Heavy or binge-pattern use carries significant risk of stimulant psychosis — paranoia, hallucinations, and delusional thinking.[15] Sustained dopamine overstimulation in reward pathways is the established driver.
Post-use psychiatric symptoms documented in NEH cases include anxiety, feelings of persecution, anhedonia, and psychomotor slowing.[7] These may persist for days after heavy use.
Tolerance and dependence
Tolerance to hexedrone's stimulant effects develops with repeated use.[6] Community estimates place tolerance half-life at 3–7 days and full reset at 1–2 weeks.[6] Cross-tolerance occurs with dopaminergic stimulants — amphetamines, cocaine, and other cathinones.
Dependence liability is moderate to high, driven by potent DAT blockade. Physical dependence is moderate.inferred The compulsive redosing pattern encourages binge use, and withdrawal follows a dopaminergic rebound effect: depression, irritability, cognitive fatigue, excessive sedation, and appetite enhancement.[7]
Drug interactions
No published interaction studies exist for hexedrone or N-ethylhexedrone. All risks below are class-level inferences.safety citation needed
MAO inhibitors block a key enzyme that breaks down catecholamines. Combined with hexedrone, they can cause dangerous catecholamine accumulation leading to life-threatening blood pressure spikes. This combination is potentially fatal.
Other stimulants — amphetamines, cocaine, other cathinones, high-dose caffeine — add cardiovascular strain on top of hexedrone's own: compounded rapid heart rate, elevated blood pressure, and overheating. Both published fatalities involved co-administered substances.[8][5]
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) may slow hexedrone's clearance, raising blood levels and increasing toxicity risk.[16]
Serotonergic agents (SSRIs, SNRIs, triptans) carry a theoretical risk of serotonin overload — a potentially life-threatening overheating and seizure response. Hexedrone's strong preference for dopamine over serotonin transporters[1] makes this lower-risk than with mixed-mechanism cathinones.
Blood pressure medications may be counteracted by hexedrone's sympathomimetic cardiovascular effects.
Contraindications
No contraindication data have been confirmed for hexedrone. The following are class-level inferences.safety citation needed
Heart disease — arrhythmia, cardiomyopathy, coronary artery disease, uncontrolled high blood pressure, atherosclerosis — is an absolute contraindication. Pre-existing cardiac conditions were a co-factor in one published fatality.[5]
Concurrent MAOI use is an absolute contraindication.
Kidney impairment is a relative contraindication, given acute kidney failure documented in one fatal case.[8]
Seizure disorders warrant caution — stimulant cathinones may lower seizure threshold.[5]
Psychiatric conditions — psychotic disorders, bipolar disorder, severe anxiety — are relative contraindications due to stimulant-induced psychosis risk.[15]
Pregnancy and breastfeeding are absolute contraindications due to unknown developmental risks and expected cardiovascular and thermal stress.safety citation needed
Harm Reduction[edit]
Forms & Identification
Hexedrone appears as a white crystalline powder, visually identical to dozens of other cathinone stimulants. Because hexedrone has minimal market presence compared to N-ethylhexedrone, mislabeling is a realistic concern — one published fatality involved a powder initially misidentified as cocaine.[8]
Reagent testing can confirm the cathinone class but cannot reliably distinguish hexedrone from structurally similar compounds. Quantitative analysis through drug checking services, where available, is the only reliable way to verify both identity and purity. Given the narrow gap between recreational and dangerous blood concentrations, knowing exactly what is in a sample is unusually important for this compound.
Guidelines
- Test every batch with reagent kits and, where possible, a drug checking service
- Weigh doses with a milligram-precision scale — do not estimate by eye
- Pre-portion a single session's worth and physically separate the remainder before dosing
- Stay hydrated but do not overhydrate — aim for moderate, steady fluid intake
- Eat a meal before use; cathinone stimulants suppress appetite during the session
- Set a firm cutoff time — the compulsive redosing urge is consistently reported as stronger than the actual high warrants
- Avoid physical exertion in warm environments; monitor body temperature if possible
- Do not use alone; inform someone of what was taken and when
Set & Setting
Hexedrone's short peak and intense redosing urge make environmental planning especially important. Using in a setting where additional doses are easily accessible increases the probability of binge use. Stimulant-naive individuals should expect stronger cardiovascular effects at equivalent doses.
A sober companion can help monitor for escalating heart rate, overheating, or behavioral changes the user may not recognize during the stimulant peak. Quiet, temperature-controlled environments reduce the risk of dangerous overheating — documented as a cause of death in one fatality.[8]
Aftercare & integration. The post-stimulant comedown from hexedrone-class cathinones involves a predictable dopamine rebound effect: low mood, fatigue, irritability, and difficulty concentrating. These effects are temporary but can be distressing, especially after binge use.
Prioritize sleep — even if it feels unattainable immediately after the stimulant wears off. Eat nutrient-dense food, hydrate steadily, and avoid caffeine or other stimulants during the recovery window. Physical and emotional baseline typically returns within 1–3 days for single-session use; repeated or binge use extends recovery proportionally. If low mood, anhedonia, or paranoid thoughts persist beyond several days, seek professional support — these symptoms have been documented in clinical cases of N-ethylhexedrone intoxication.[7]
Recovery & Support
Hexedrone's compulsive redosing pattern and dopamine-driven reinforcement can establish habitual use that is difficult to interrupt without structured support. If use has become regular or binge-pattern, professional help improves outcomes.
Stimulant-specific resources include SAMHSA's National Helpline (1-800-662-4357, US), local addiction services, and peer support groups. Cognitive behavioral therapy has the strongest evidence base for stimulant use disorders. There is no pharmacological treatment specific to cathinone dependence, but structured support for the psychological dimensions is effective.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, body temperature hot enough to feel through clothing, extreme confusion or aggression, and breathing difficulty all require immediate help. An uncomfortable but safe stimulant experience involves anxiety and rapid heartbeat that stabilize; an emergency involves symptoms that escalate or do not resolve.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool environment and remove excess clothing
- 3. If unconscious but breathing, place in the recovery position
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (or "a synthetic cathinone stimulant" if unsure), the amount taken if known, the time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies from prosecution.
Legal Status[edit]
Hexedrone is not individually scheduled under most national or international frameworks, but falls within generic cathinone controls in several jurisdictions. Its N-ethyl structural analog, N-ethylhexedrone, has received specific scheduling at national and international levels, reflecting its greater market prevalence and associated harms.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not individually scheduled; Federal Analogue Act applies | Hexedrone is not listed in the DEA Controlled Substances schedules. It is subject to prosecution under the Federal Analogue Act (21 U.S.C. § 813) when intended for human consumption. N-ethylhexedrone was permanently placed in Schedule I on June 1, 2022.[9][17] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under the generic cathinone catch-all clause.[6] |
| Germany | Controlled (NpSG) | Controlled under the Neue-psychoaktive-Stoffe-Gesetz since November 26, 2016. Production and import with intent to market, administration to others, and trading are punishable. Possession is prohibited but not penalized.[6] |
| United Nations | Not individually scheduled | N-ethylhexedrone was added to the UN Convention on Psychotropic Substances Schedule II in March 2020.[10] Hexedrone was not included. |
| Canada | Likely controlled (class provision) | N-ethylhexedrone is Schedule I. Hexedrone's individual status is not confirmed; likely captured under cathinone class provisions.citation needed |
| Australia | Likely controlled (class provision) | Synthetic cathinones are broadly controlled under state/territory legislation and the Therapeutic Goods Act. Specific scheduling of hexedrone by name not confirmed.citation needed |
Analog liability
In jurisdictions with structural analog legislation — notably the US Federal Analogue Act — hexedrone's status depends on whether it is deemed "substantially similar" to a scheduled cathinone. Given its single-carbon difference from Schedule I N-ethylhexedrone, prosecution under analog provisions is probable but untested for hexedrone specifically.
Legal status for novel psychoactive substances changes frequently. The information above reflects currently available data and is not legal advice. Verify current status in the relevant jurisdiction before making any decisions.
references
- [1]
- [2] ^Persson M, Vikingsson S, Kronstrand R, Green H (2024) Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. — Drug Testing and Analysis doi:10.1002/dta.3547
- [3]
- [4] ^abBłażewicz A, Bednarek E, Sitkowski J, Popławska M, Stypułkowska K, Bocian W, Kozerski L (2017) Identification and structural characterization of four novel synthetic cathinones: α-methylaminohexanophenone (hexedrone, HEX), 4-bromoethcathinone (4-BEC), 4-chloro-α-pyrrolidinopropiophenone (4-Cl-PPP), and 4-bromo-α-pyrrolidinopentiophenone (4-Br-PVP) after their seizures — Forensic Toxicology doi:10.1007/s11419-017-0360-2
- [5]
- [6]